Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Lilly’s oral interleukin exit hints at a dicey future
Liver toxicity with the group’s oral IL-17 inhibitor could raise doubts about projects from Dice, Leo and Sanofi.
